FDA committee recommends AstraZeneca and Sanofi’s RSV prophylactic nirsevimab
The committee overwhelmingly supported nirsevimab’s risk-benefit profile in both newborns and infants entering their first RSV season.

The committee overwhelmingly supported nirsevimab’s risk-benefit profile in both newborns and infants entering their first RSV season.
The vaccine has been developed by WestVac Biopharma along with the West China Medical Center and Sichuan University.
The Asia-Pacific pharma industry experienced a 2% rise in new job postings in Q1 2023 compared with the previous quarter,…
Oragenics secures CQDM funding for Covid-19 vaccine antigen development
Revised EU/Pfizer/BioNTech Covid-19 vaccine deal may lead to a Comirnaty monopoly
XtalPi announces $250m AI drug discovery collaboration with Eli Lilly
University of Sydney will use AI to boost cancer drug research